Received Aug 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Alternatives Sites for Intramuscular Administration of Shingrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of vaccine administered at inappropriate site in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. The patient's past medical history included lymph node excision (lymph nodes removed from patient's arm). Concurrent medical conditions included cancer. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccine administered at inappropriate site (Verbatim: Alternatives Sites for Intramuscular Administration of Shingrix). The outcome of the vaccine administered at inappropriate site was not applicable. Additional Information: GSK receipt date: 01-AUG-2025 Pharmacist had an adult female patient who is on cancer treatment and she has had her lymph nodes removed from her arm. Patient would like to received Shingrix first dose but she declined to have the injection on her deltoid muscle which led to vaccine administered at inappropriate site.
Cancer
Medical History/Concurrent Conditions: Lymph node excision (lymph nodes removed from patient's arm)